English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/169086
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

AuthorsGarcía-Sanz, Ramón; Corchete, Luis A.; Alcoceba, Miguel; Chillón, M. del Carmen; Jiménez, Cristina ; Prieto-Conde, Isabel; García-Alvarez, María; Puig, Noemi; Rapado, Inmaculada; Barrio, Santiago; Oriol, Albert; Blanchard, María Jesús; Rubia, Javier de la; Martínez, Rafael; Lahuerta, Juan José; González, Marcos ; Mateos, Maria Victoria; San Miguel, Jesús F. ; Martínez-López, Joaquín; Sarasquete, María Eugenia
KeywordsGenome‐wide association studies
Thalidomide‐induced peripheral neuropathy
Multiple myeloma
Bortezomib‐induced peripheral neuropathy
Issue Date2017
PublisherJohn Wiley & Sons
CitationHematological Oncology 35(4): 746-751 (2017)
AbstractBortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients. However, treatment-induced peripheral neuropathy (TiPN) is a common adverse event associated with them. Risk factors for TiPN in MM patients include advanced age, prior neuropathy, and other drugs, but there are conflicting results about the role of genetics in predicting the risk of TiPN. Thus, we carried out a genome-wide association study based on more than 300 000 exome single nucleotide polymorphisms in 172 MM patients receiving therapy involving bortezomib and thalidomide. We compared patients developing and not developing TiPN under similar treatment conditions (GEM05MAS65, NCT00443235). The highest-ranking single nucleotide polymorphism was rs45443101, located in the PLCG2 gene, but no significant differences were found after multiple comparison correction (adjusted P =.1708). Prediction analyses, cytoband enrichment, and pathway analyses were also performed, but none yielded any significant findings. A copy number approach was also explored, but this gave no significant results either. In summary, our study did not find a consistent genetic component associated with TiPN under bortezomib and thalidomide therapies that could be used for prediction, which makes clinical judgment essential in the practical management of MM treatment.
DescriptionGEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.
URIhttp://hdl.handle.net/10261/169086
Identifiersdoi: 10.1002/hon.2337
e-issn: 1099-1069
issn: 0278-0232
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.